The underground weight-loss market is abuzz with a new, unapproved compound called retatrutide. Originally developed by pharmaceutical giant Eli Lilly, the drug has found a loyal following despite still being in clinical trials. Retatrutide, nicknamed "Triple G" for its ability to work on three hormone receptors, has been hailed as a game-changer for weight loss. Participants in phase II trials have reported significant reductions in body weight and improvements in metabolic markers.
Those taking the drug claim it allows them to lose weight without extreme appetite suppression, unlike other GLP-1 type drugs like semaglutide and tirzepatide. The "Triple G" effect enables users to burn fat while still feeling full, making it an attractive option for those struggling with cravings or digestive issues.
Users have reported dramatic results, including 24.2% weight loss over a 48-week period, outperforming other drugs in clinical trials. Fitness enthusiasts and athletes are particularly drawn to the drug's ability to boost energy levels and improve exercise performance.
While Eli Lilly is completing phase III trials and expects FDA approval by late 2026 or early 2027, unofficial sales of retatrutide continue to thrive online. Middlemen retailers like Jake Terry claim to be making the drug more accessible, as long as it's for research purposes only.
However, regulatory warnings have been issued against companies selling retatrutide directly to consumers, citing unknown quality and potential harm to health. The FDA cautions that purchasing these products is not advisable until they receive approval.
Producers of such chemicals can glean the drug's molecular structure from patent literature submitted by pharmaceutical sponsors. Online retailers risk infringing on patents protected by pharmaceutical companies.
Despite these risks, users like Jake Terry argue that making the drug more accessible could lead to improved health outcomes.
Those taking the drug claim it allows them to lose weight without extreme appetite suppression, unlike other GLP-1 type drugs like semaglutide and tirzepatide. The "Triple G" effect enables users to burn fat while still feeling full, making it an attractive option for those struggling with cravings or digestive issues.
Users have reported dramatic results, including 24.2% weight loss over a 48-week period, outperforming other drugs in clinical trials. Fitness enthusiasts and athletes are particularly drawn to the drug's ability to boost energy levels and improve exercise performance.
While Eli Lilly is completing phase III trials and expects FDA approval by late 2026 or early 2027, unofficial sales of retatrutide continue to thrive online. Middlemen retailers like Jake Terry claim to be making the drug more accessible, as long as it's for research purposes only.
However, regulatory warnings have been issued against companies selling retatrutide directly to consumers, citing unknown quality and potential harm to health. The FDA cautions that purchasing these products is not advisable until they receive approval.
Producers of such chemicals can glean the drug's molecular structure from patent literature submitted by pharmaceutical sponsors. Online retailers risk infringing on patents protected by pharmaceutical companies.
Despite these risks, users like Jake Terry argue that making the drug more accessible could lead to improved health outcomes.